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Background: Statins are lipid-lowering agents that also exhibit pleiotropic effects in decreasing oxidative stress and
inflammation. There have been several published studies reporting the use of statins in the treatment of asthma
patients, but their results are not consistent. The aim of this study is to determine whether statins are beneficial for
asthma administration, and explore the potential covariables that may affect their clinical effectiveness.
Methods: A systematic literature search was performed in PubMed, Embase and Cochrane Center Register of
Controlled Trials from inception to September 2012. Randomized controlled trials (RCT), retrospective studies and
controlled clinical trials which reported the use of statins in the treatment of asthma patients were eligible. Quality
evaluation was conducted for RCT using Jadad criteria.
Results: A total of 18 articles were included. In our study, we found no conclusive evidence to demonstrate that
statins could enhance the lung function in asthmatics, although, they may reduce airway inflammation.
Additionally, the results were not consistent across studies with respect to symptoms, quality of life, maintenance
medication, asthma hospitalization/emergency department (ED) visits.
Conclusions: Statins may reduce airway inflammation in asthmatics, without having a significant effect on lung
function. Further large sample and multicenter clinical trials are needed to confirm this and to see if there are more
responsive phenotypes of asthma.
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Chronic airway inflammation plays a major role in the
pathophysiology of asthma, and is also associated with
airway hyperresponsiveness. Glucocorticoids,leukotriene
modifiers, and anti-IgE antibody are the main anti-
inflammatory medications to keep asthma under clinical
control chiefly through their anti-inflammatory effects
[1,2]. However, specific subpopulations of individuals in-
cluding smokers [3], obese asthmatics [4,5] and non-
Th2-high asthmatics [6] respond poorly to the above
medications.
Statins,inhibitors of hydroxymethylglutaryl coenzyme
A (HMG-A) reductase,can inhibit the mevalonate
pathway and the synthesis of downstream intermediates
including farnesylpyrophosphate (FPP) and geranylgera-
nylpyrophosphate (GGPP), which post-translationally* Correspondence: hm6114@126.com; yaoxin@njmu.edu.cn
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reproduction in any medium, provided the ormodify small guanosine triphosphatases (GTPases) [7,8].
GTPases may play a role in the pathophysiology of
asthma, because they could enhance airway smooth
muscle contraction and proliferation, and increase airway
hyperresponsiveness [9,10]. Studies have demonstrated
that statins reduce the total inflammatory cell infiltrate
and eosinophilia in bronchoalveolar lavage fluid in an
animal model of asthma [11] and inhibit the airway
smooth muscle proliferation and contraction in vitro
[12].
In 2009, a retrospective study by Stanek et al. [13]
showed that statin therapy was independently associated
with a significant 33% relative risk reduction for recur-
rent asthma-related hospitalization/emergency depart-
ment (ED) events. Recently, several studies have been
performed in asthmatics to investigate the clinical effect-
iveness of statins in asthma. Some studies suggested that
short-term treatment with statins could increase lung
function, enhance the anti-inflammatory effect of
inhaled corticosteroids (ICS), and improve the Asthmad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Life Questionnaire (AQLQ) [14-16]. However, other
studies failed to replicate these results [17-19]. There-
fore, we performed a systematic review to see whether
asthmatic patients could benefit clinically from statins,
and explore potential factors that may affect their clin-
ical effectiveness.
Methods
Search strategies
A systematic literature search was conducted by two
investigators (C Y and Y T) independently in Pubmed,
Embase and Corchrane Center Register of Controlled
Trials from database inception to September 2012, with
the reference lists browsed at the same time. The follow-
ing terms were used for statins: “hydroxymethylglutaryl
coenzyme a reductase inhibitors”, “HMG-CoA reductase
inhibitors”, “simvastatin”, “lovastatin”, “pravastatin”, “flu-
vastatin”, “atorvastatin”, “cerivastatin”, “rosuvastatin”,
“pitavastatin”, “statin”, “statins” and “compactin”. The
following terms were used for asthma:“asthma”, “bron-
chial spasm”, “bronchoconstriction”, “bronchial hyper-
reactivity”, “airway inflammation”, “wheeze” and
“wheezing”. There was no language restriction.
Study selection criteria
Studies which selected asthmatics exposed to statins
as the trial group and asthmatics unexposed to statins
as the control group, or made assessment on the ef-
fect of statins by comparing it with the baseline were
eligible. Also abstracts without full text that provided
information on asthmatics about lung function out-
comes, airway inflammation, or the quality of life
were included.
Studies that conducted in vitro or in animal models
were excluded (Additional file 1).
Data extracted
According to the search strategy and select criteria, two
investigators (C Y and Y T) respectively reviewed the
titles, abstract and full articles, we obtained the eligible
studies. However, 10 studies, including studies only pub-
lished as abstracts which did not provide enough infor-
mation and intervention studies without a placebo
control were discussed by the authors and their inclu-
sion resolved by consensus after review by X Y. For each
study, relevant data were directly derived from the paper
including the demographic data, administration, type of
study, duration of treatment, outcomes assessment, con-
clusions etc.
Quality evaluation
Quality evaluation was conducted for each randomized
controlled trial. Four RCT studies were excluded fromthe quality evaluation because they were published in
the form of an abstract and therefore we were unable
to extract enough information from them. Quality
evaluation is consistent with the Jadad criteria (scoring
was made according to descriptions for randomization,
double blinding, withdrawals and dropouts, maximum
score 5) [20]. A poor score was defined as less than 2,
and a good score was defined as 3–5 (Table 1).Results
Figure 1 shows the results of the systematic literature
search. A total of 1032 articles were reviewed, of which
877 were irrelevant and 97 were duplicate studies, and
therefore they were excluded from the study after
screening the titles. Of the remaining 58 relevant stud-
ies, 21 were concerned with animal experiments, 11
were reviews, 5 were in vitro trials, and 3 were not
related to asthma. Finally, 18 articles were included in
our study: 9 RCT (4 published as abstracts), 7 retro-
spective studies (4 published as abstracts), and the
remaining two were controlled clinical trials (published
as abstracts) comparing statins with the placebo or base-
line. There was a significant difference in the method-
ology, demographic data, baseline characteristics and
outcome measures between the retrospective studies and
the RCT studies. Additionally, insufficient data were
available in the 5 RCT studies whose designs were rela-
tively rigorous by scoring four or more points. We tried
to contact the authors by email to obtain the original
data without success. A meta-analysis was, therefore, im-
practicable and systematic qualitative appraisal was
performed.Lung function
Of the eight RCT studies reporting lung function
results in asthma patients, six showed that statins did
not improve lung function [16,19,21-24]. One demon-
strated that simvastatin was associated with minor im-
provement in FEV1 (p<0.01) in the absence of steroids
[25] and another demonstrated that atorvastatin pro-
moted clinical and functional improvement in night-
time symptoms, cough, daily symptoms and FEV1 in
severe asthma patients [14]. Three retrospective studies
showed inconsistent results. Pagovich et al. demon-
strated that statins were associated with improvement
in peak flow (PF) measurements (p<0.0001) [26],
whereas Adams et al. suggested that statins did not
have a beneficial effect on lung function in asthma
patients [27]. Ostroukhova et al. intriguingly reported
that FEV1 became worse in asthma patients who
received statins [18]. Finally, in a small controlled clin-
ical trial with only 9 asthmatic patients, atorvastatin
failed to improve lung function [28]. Overall, there
Table 1 Results of the quality evaluation for selected RCT studies
Study randomisation double-blind description dropouts Jadad Scale
Menzieset al., [21] 1 2 1 4
Hothersallet al., [22] 1 2 1 4
Maneechotesuwan et al., [15] 1 2 1 4
Cowan et al., [25] 1 2 1 4
Braganza et al., [16] 2 2 1 5
Jadad criteria allocate a point each for randomization, double-blind design, and description of dropouts. If randomization and double-blind concealment are
assured, an additional 2 points are added. If randomization or double-blind concealment is not assured, a point is deducted for each. A trial with a score of 3 or
more is regarded as high quality. Data from trials with scores of 3 or more were grouped and analysed separately from those scoring less than 3.
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in asthmatic patients (Table 2).
Airway inflammation
Three randomized double-blind clinical trials demon-
strated that statins could decrease induced sputum cell
counts in asthmatics, including eosinophils [15,25] and
macrophages [22]. Evidence also suggested that simvas-
tatin had an anti-inflammatory activity in reducing
serum ECP and CRP levels [29]. Additionally, Menzies
et al. demonstrated that simvastatin led to a 0.86 geo-
metric mean fold decrease (95% CI, 0.7 to 1.04; P=0.15)
in fractional exhaled nitric oxide (FENO), and a −0.18Pubmed (n=90), Embase (n=927), Cochra
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Figure 1 Results of the systematic literature search.doubling dilution shift (95% CI, –1.90 to 1.55; P=1.0)
in methacholine hyperresponsiveness [21]. In contrast
Braganza et al. [16] showed that the cell counts in
induced sputum were similar after atorvastatin and pla-
cebo treatment. Overall, statins reduced airway inflam-
mation in asthma patients (Table 3).
Comparison of symptoms and quality of life
Braganza et al. [16] compared asthmatics treated with
atorvastatin (40mg/day) with those treated with placebo
in a randomized double-blind parallel group trial. They
reported that there was a significant improvement in
ACQ score and AQLQ score at 4 weeks in thene(n=15)
ved
Records excluded
(n=877)
Full-textarticles excluded(n=40)
Animal experimentation(n=21)
Reviews (n=11)
Trials in vitro (n=5)
Not asthma (n=3)
hesis
=9)
)
Table 2 Studies which report lung function after statin treatment
Study Study type Group Sample
(Trial/Control)
Duration of
treatment
Results (statin group
compared with the
control group)
Ostroukhova et al., [18] Retrospective study Statin exposed vs statin unexposed 50(24/26) 2 years 3% to 5% median
worsening of FEV1 ↓
Braganza et al., [16] RCT Atorvastatin(40mg/day) vs placebo 71 4weeks No significant difference
Moskovljevicet al., [28] Controlled clinical trial Atorvastatin(10mg/day) vs placebo 9 4 weeks No significant difference
Menzies et al., [21] RCT Simvastatin(20mg/day,40mg/day)vs
placebo
16 4 weeks No significant difference
Hothersall et al., [22] RCT Atorvastatin(40mg/day) vs placebo 54 8 weeks No significant difference
Cowan et al., [25] RCT Simvastatin(40mg/day) vs placebo 43 4 weeks PEF, FEV1 (p<0.01) ↑
Pagovich et al., [26] Retrospective study Atorvastatin, simvastatin vs baseline 70 4 weeks PF (p<0.0001) ↑
Foumani et al., [19] RCT Atorvastatin(40mg/day) vs placebo 67 8 weeks No significant difference
Fahimi et al., [23] RCT Atorvastatin(10mg/day) vs placebo 17 4 weeks No significant difference
Feschenko et al., [14] RCT Atorvastatin+ICS+Salbutamol
vs ICS+salbutamol
31 4 weeks Morning PEF, FEV1 ↑
Adams et al., [27] Retrospective study Statin exposed vs statin unexposed 539 Not mentioned No significant difference
Moini et al., [24] RCT Atorvastatin(40mg/day) vs placebo 62 8 weeks No significant difference
PEF=Peak Expiratory Flow; FEV1= Forced expiratory volume in one second; PF= Peak flow.
↑ The lung function was improved in statin group compared with the control group, ↓ an opposite result.
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maintained at 8 weeks. Another study found that ACQ
score was lower in the simvastatin group compared with
the placebo group in the absence of steroids [25].
Hothersall et al. [22] showed that there was no signifi-
cant difference in ACQ score or AQLQ score between
atorvastatin and placebo treatment (Table 4).
Asthma hospitalization/ED visit, maintenance medications
and morbidity
Five studies reported the outcomes of asthma
hospitalization/ED visits. Of them, three studies showed
that statin exposure was independently associated with a
reduction in asthma-related hospitalization/ED visits asTable 3 Studies which report airway and serum inflammation
Study Study type Group S
(Tria
Braganza et al., [16] RCT Atorvastatin(40mg/day) vs placebo
Menzies et al., [21] RCT Simvastatin(20mg/day,40mg/day)
vs placebo
Hothersall et al., [22] RCT Atorvastatin(40mg/day) vs placebo
Maneechotesuwan
et al., [15]
RCT Simvastatin(10mg/day vs placebo 47
Cowan et al., [25] RCT Simvastatin(40mg/day) vs placebo
Al Obaidiet al., [29] Controlled
clinical trial
Simvastatin vs baseline
PC10= Concentration of methacholine that reduces FEV1 by 10%; FENO= Fractional
CRP=C-reactive protein.
↓ The airway and serum inflammation levels were lowering after statins treatment.indicated by multivariate analysis [13,30,31], whilst the
remaining two studies reported contradictory results,
one of which reported that statins increased the risk of
asthma-related hospitalization/ED visits [18], and the
other reported that statins could not reduce this risk,
after analysis adjusted for age, sex, baseline severity and
comorbidities [17]. An additional two studies showed
that statins were associated with a reduction in albuterol
or salbutamol use [23,26]. This study also contradicted
that of Christiansen et al. who reported that statins did
not lead to a decrease the dosage of corticosteroids [17].
Ostroukhova et al. reported that salbutamol was used
more frequently in the statin group as compared with
the control group [18]. Moskovljevic et al. [28] andafter statin treatment
ample
l/Control)
Duration
of treatment
Results (statin group
compared with the
control group)
71 4 weeks No significant difference
16 4 weeks 0.86 geometric mean fold decrease in FENO
and −0.18 doubling dilution shift in PC10 ↓
54 8 weeks macrophage count (p=0.029) and
sputum fluid leucotriene B4 (p=0.014) ↓
(25/22) 8 weeks Sputum eosinophil percentages (p=0.02) ↓
43 4 weeks Sputum eosinophils (p=0.033) ↓
20 Not mentioned ECP and CRP ↓
of exhaled nitric oxide; ECP=Serum eosinophil cationic protein ,
Table 4 Studies which report the comparison of symptoms and quality of life
Study Study type Group Sample
(Trial/Control)
Duration of
treatment
Results (statin group compared
with the control group)
Braganza et al., [16] RCT Atorvastatin(40mg/day) vs placebo 71 4 weeks ACQ and AQLQ (p=0.005) ↑
Hothersall et al., [22] RCT Atorvastatin(40mg/day) vs placebo 54 8 weeks No significant difference
Cowan et al., [25] RCT Simvastatin(40mg/day) vs placebo 43 4 weeks ACQ (p=0.037) ↓
ACQ= Asthma Control Questionnaire; AQLQ= Asthma Quality of Life Questionnaire.
↑ The symptoms and quality of life were improved in statin group compared with the control group, ↓ an opposite result.
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in patients receiving atorvastatin compared with those
receiving the placebo. Additionally, a retrospective study
showed that the statin groups had more nocturnal awa-
kenings than controls (Table 5) [18].
Discussion
A total of 18 studies have been included in this research.
Of these, only three studies demonstrated that statins
could enhance the lung function in asthmatics, whilst 15
studies failed to support this. There was a tendency that
statins were associated with reduced airway inflamma-
tion, suggesting that statins may be used as a supple-
ment for anti-inflammatory treatment of asthma at
present. The effects of statins were inconsistent in differ-
ent studies with respect to the symptoms, quality of life,
asthma hospitalization/ED visits and maintenance medi-
cations. Further large placebo-controlled studies areTable 5 Studies which report asthma hospitalization/ED visit,
Study Study type Group
Huang et al., [30] Retrospective study Statin exposed vs
statin unexposed
Ostroukhova et al., [18] Retrospective study Statin exposed vs
statin unexposed
Christiansen et al., [17] Retrospective study Statin exposed vs
statin unexposed
Stanek et al., [13] Retrospective study Statin exposed vs
statin unexposed
Moskovljevic et al., [28] Controlled clinical
trial
Atorvastatin(10mg/day)
vs placebo
Pagovich et al., [26] Retrospective study Atorvastatin, simvastatin
vs baseline
Fahimi et al., [23] RCT Atorvastatin(10mg/day)
vs placebo
Feschenko et al., [14] RCT Atorvastatin+ICS+Salbutamol
vs ICS+salbutamol
Lokhandwala et al., [31] Retrospective study Statin exposed vs
statin unexposed
↑ Statin have bad effects on asthma patients, ↓ an opposite result.needed in well-defined subsets of asthmatics patients
treated or not treated with corticosteroids before a con-
sensus can be reached.
The clinical status of participants may affect the clin-
ical effectiveness of statins, such as the severity of
asthma, age of participants, smoking status and obesity.
Feschenko et al. selected 31 severe asthma as the sub-
jects and found that atorvastatin significantly improved
clinical and functional outcomes [14], which indicated
statins might be effective in severe asthma. However, the
results of other included studies, in which the partici-
pants were mostly mild to moderate asthmatics did not
show a beneficial effect of statins. Further studies on se-
vere asthmatics are needed to confirm this.
A retrospective study found that increasing age was in-
dependently associated with an increased risk of
hospitalization for asthma patients [30]. This may be
due to poor asthma control and medication compliancemaintenance medications use (steroid or salbutamol) etc
Sample
(Trial/Control)
Duration of
treatment
Results (statin group compared
with the control group)
11808(3965/7843) 4.66 ± 2.32
years
Hospitalization/ED visit
(p=0.006) ↓
50(24/26) 2 years Maintenance medication (p=0.005),
nocturnal awakenings(P=0.001),
office visits(P=0.003) and albuterol
use (p=0.001) ↑
43158(7783/35375) Not
mentioned
Risk ratios were 1.2 for
Hospitalizations/ED visits
and 1.17 for oral corticosteroid
diepemsing ↑
6574(2103/4471) 1 year Hospitalization/ED visit (p < 0.001) ↓
9 4 weeks Morbidity ↓
70 4 weeks Albuterol use(p<0.0001) ↓
17 4 weeks Morbidity (p=0.42) ↓
31 4 weeks Night symptoms, cough, dialy
symptoms and use of salbutamol
(p<0.05) ↓
1437(479/958) 1 year Hospitalization/ED visit (p=0.0059) ↓
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effects of statins.
In addition, some results have shown that ex-smokers
and current smokers have a lower decline in FEV1 and
FVC when taking statins [35,36]. Furthermore, Braganza
et al. showed that in smokers with mild to moderate
asthma, short term treatment with statins could improve
asthma quality of life [16]. Cigarette smoking in asthma
is associated with a reduced sensitivity to ICS [3], so sta-
tins may act as an effective therapy for asthma patients
who have reduced sensitivity to ICS. Finally, studies have
demonstrated that obesity was associated with poor
asthma control [37,38] and poor response to ICS treat-
ment [39]. Statins are lipid-lowering agents and may be
used to relieve the symptoms of obesity-related asthma.
Our analysis of the clinical data reported to date indi-
cates marked differences in study design. Statins inhibit
contraction and migration of human airway smooth
muscle cells [40]. It was estimated that smooth muscle
cells of the mouse aorta divide with a half-life in the
range of 300 [41] to 800 [42] days, and this half-life is
much longer than the duration of treatment of most
clinical studies (4 or 8 weeks). Therefore, if these results
are translated to man, the therapeutic effects of statins
in asthma may only become apparent after long-term
treatment. Long-term studies should be designed to in-
vestigate the long- term effects of statins.
There is evidence that the therapeutic effects of indi-
vidual statins are different. For example, simvastatin and
lovastatin are more effective against human smooth
muscle cells than atrovastatin in vitro [43]. Furthermore,
cerivastatin has the greatest potency in reducing NF-κB-
mediated inflammation [44]. Lipophilic statins such as
atorvastatin and simvastatin have much greater effects
on inflammatory responses in human monocytes in vitro
and mice leukocytes in vivo than hydrophilic pravastatin
[45]. Thus, new clinical trials should compare the efficacy
of different statins since these may have different effects.
Animal experiments have confirmed the effective dosage
of statins used in animal asthma models, the high-dose
being 40mg/kg for simvastatin [11,46] in comparison
with 4mg/kg for lovastatin [10]. The maximum recom-
mended dosage of atorvastatin is 80mg/day in man.
However, the dosage of statins was below 40mg/day in all
eligible studies. In addition, the effect of the small sample
size in most of the reported studies must not be ignored.
There are certain limitations of our study. We used a
loose selection criteria; for example, abstracts and stud-
ies with comparison against baseline only were also
selected, because there have not been many studies in
this area. In addition, we were unable to conduct a
meta-analysis due to limited information, and therefore
we could not provide statistically significant evidence to
confirm the effectiveness of statins.In conclusion, statins may reduce airway inflammation
in asthmatics, although there is not sufficient evidence
to make a conclusion that statins can improve lung
function. A sub-population of asthmatics, including
smokers and obese individuals who respond poorly to
ICS may respond preferentially to statins. The immuno-
modulating property of statins may shed new light on
their promising use in the treatment of asthma. Large
sample and multicenter clinical trials in selected specific
subpopulations will be needed to investigate the full po-
tential effects of statins in asthma treatment.
Additional file
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